A double-blind trial of colchicine in Behçet's syndrome.

@article{Yurdakul2001ADT,
  title={A double-blind trial of colchicine in Behçet's syndrome.},
  author={S. Yurdakul and C. Mat and Y. T{\"u}z{\"u}n and Y. Ozyazgan and V. Hamuryudan and O. Uysal and M. Senocak and H. Yazici},
  journal={Arthritis and rheumatism},
  year={2001},
  volume={44 11},
  pages={
          2686-92
        }
}
OBJECTIVE Colchicine is a widely used treatment for Behçet's syndrome, even though in a previous 6-month controlled study, it was shown to be effective only in controlling erythema nodosum and arthralgias. We reassessed the effect of colchicine in Behçet's syndrome in a study conducted among a larger group of patients for 2 years. METHODS We randomized 116 patients with Behçet's syndrome (60 male/56 female), who had active mucocutaneous disease without eye or major organ involvement, to… Expand
A double-blind trial of depot corticosteroids in Behçet's syndrome.
TLDR
Low-dose depot corticosteroids did not have any beneficial effect on genital ulcers, however, it was useful in controlling erythema nodosum lesions, especially among the females. Expand
Colchicine versus placebo in Behçet’s disease: randomized, double-blind, controlled crossover trial
Abstract The effect of colchicine was evaluated in a large cohort of Behçet’s disease (BD) patients and compared to placebo. In a randomized, double-blind, controlled crossover trial, 169 patientsExpand
Colchicine versus placebo in Behçet’s disease: randomized, double-blind, controlled crossover trial
The effect of colchicine was evaluated in a large cohort of Behçet’s disease (BD) patients and compared to placebo. In a randomized, double-blind, controlled crossover trial, 169 patients withoutExpand
Apremilast for Behçet's syndrome--a phase 2, placebo-controlled study.
TLDR
Apremilast was effective in treating oral ulcers, which are the cardinal manifestation of Behçet's syndrome, and the risk of uncommon serious adverse events was low. Expand
Colchicine in Behçet Syndrome: A Longterm Survey of Patients in a Controlled Trial
TLDR
Continuous use of colchicine, even when initiated at an early disease stage, does not seem to decrease the use of immunosuppressives in the long term. Expand
Apremilast for the treatment of Behcet’s syndrome
TLDR
This review covers the current data on the efficacy and safety of apremilast in BS patients with mucocutaneous involvement coming from a Phase 2 placebo controlled trial as well as the patient important outcomes reported in the same trial. Expand
A new Mucocutaneous Activity Index for Behçet's disease.
TLDR
The mucocutaneous activity index may help decision-making process for treatment strategies in BD patients and may help decide the best way to treat patients with Beh-çet's disease. Expand
Adverse events during oral colchicine use: a systematic review and meta-analysis of randomised controlled trials
TLDR
Colchicine increases the rate of diarrhoea and gastrointestinal adverse events but does not increase the rates of liver, sensory, muscle, infectious or haematology adverse events or death. Expand
Ustekinumab for Behçet's disease.
TLDR
Ustekinumab seems to be efficient and safe for patient with BD and refractory OU although relapses are frequent, and the proportion of patients with complete response (CR), defined as no oral ulcer, at week 12. Expand
Value of colchicine as treatment for recurrent oral ulcers: a systematic review.
  • M. Cabras, M. Carrozzo, +4 authors P. Arduino
  • Medicine
  • Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
  • 2020
TLDR
Role of colchicine as treatment for idiopathic or secondary recurrent oral ulcers is still controversial and further standardized RCTs and crossover trials are needed. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 13 REFERENCES
A controlled trial of azathioprine in Behçet's syndrome.
TLDR
It is concluded that azathioprine is effective in controlling the progression of Behçet's syndrome, especially its most serious manifestation, eye disease. Expand
DOUBLE-MASKED TRIAL OF CYCLOSPORIN VERSUS COLCHICINE AND LONG-TERM OPEN STUDY OF CYCLOSPORIN IN BEHÇET'S DISEASE
TLDR
The double-masked study showed that cyclosporin was effective in treating not only the ocular manifestations of Behçet's disease but also oral aphthous ulcer, dermal lesions, and genital ulceration. Expand
Behcet Disease and the Emergence of Thalidomide
TLDR
Patients from the identified populations at risk of Behcet disease, although differing slightly in the variability of presentation depending on the areas they come from, have a more unfavorable prognosis than the patients sporadically described in the western world because of more severe uveitis, vascular changes, and demyelinating disease. Expand
Influence of age of onset and patient's sex on the prevalence and severity of manifestations of Behçet's syndrome.
TLDR
While male sex and a younger age of onset are associated with more severe disease in BS, overall, the syndrome ran an improving or stable course over 4 1/2 years. Expand
Colchicine in the treatment of the cutaneous manifestations of Behçet's disease
Five patients with Behçet's disease were satisfactorily treated with colchicine. Oral aphthosis, erythema nodosum‐like lesions and genital erosions improved greatly within a month as did laboratoryExpand
Neutrophil chemotaxis in Behçet’s syndrome
TLDR
It has been suggested that the marked cellular inflammatory response, which characterises Behcet’s syndrome (BS), may be attributable to increased neutrophil locomotion, and chemotaxis of polymorphonuclear leucocytes in BS is re-evaluated among a greater number of patients in a controlled setting. Expand
The ten-year mortality in Behçet's syndrome.
TLDR
The observed mortality of two patients in the 15-24 yr age bracket was significantly above that expected in the general population, and BS is a cause of increased mortality in the young male patients. Expand
A double blind study of colchicine in Behçet's disease.
COLCHICINE IN BEHÇET'S DISEASE
Colchicine in Behçet’s disease [letter
  • 1977
...
1
2
...